Literature DB >> 15245715

The antiphospholipid (Hughes') syndrome: changing the face of neurology.

Christos E. Lampropoulos1, Graham R.V. Hughes.   

Abstract

Hughes' syndrome (the antiphospholipid syndrome (APS)) presents with recurrent thrombosis, recurrent miscarriage and neurological disease. The major pathogenic mechanism of the syndrome is vascular obstruction (both venous and arterial) due to hypercoagulability. Neurological manifestations are prominent and are often the dominant feature. Headache, migraine and cognitive dysfunction are common while other manifestations such as dementia, epilepsy, chorea, multiple sclerosis (MS), psychiatric disease, transverse myelitis, ocular syndromes, sensorineural hearing loss and movement disorders are also associated with the syndrome. Anticoagulation therapy (either aspirin or oral anticoagulants) can lead to significant improvement.

Entities:  

Year:  2004        PMID: 15245715     DOI: 10.1016/j.ejim.2004.01.017

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  5 in total

1.  An aspirin responsive non-progressive chronic chorea.

Authors:  J A Oates; J K Lovett; N J Gutowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

Review 2.  Haematology and neurology.

Authors:  Steven Austin; Hannah Cohen; Nick Losseff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

3.  Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations.

Authors:  Mo Yin Mok; Eric Y T Chan; Woon Sing Wong; Chak Sing Lau
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

Review 4.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 5.  Hearing and dementia.

Authors:  Chris J D Hardy; Charles R Marshall; Hannah L Golden; Camilla N Clark; Catherine J Mummery; Timothy D Griffiths; Doris-Eva Bamiou; Jason D Warren
Journal:  J Neurol       Date:  2016-07-02       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.